However, because BPC-157 has not been approved by the FDA for any medical use, it cannot be legally marketed as a drug or sold as a dietary supplement
Ensuring support for research, development and validation of novel biomarker tests Research advancements on clinical assessments, psychometric testing, and emerging bloodbased and established biomarker tests are increasing the likelihood of being able to detect hallmarks of neurodegenerative diseases at their earliest stages
10.3109/09546630903341945 253 stnda OkurN.alarE.PekcanA.OkurM.AylaS
In 2025, we saw [GLP-1] use expand well beyond type 2 diabetes, with growing attention to cardiometabolic outcomes/cardiovascular risk, arthritis, sleep apnea and liver disease
Rybka J, Kupczyk D, Kedziora-Kornatowska K, et al
BPC-157 accelerates the process